Literature DB >> 21875856

Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals.

Birgitte F Sode1, Morten Dahl, Børge G Nordestgaard.   

Abstract

AIMS: Myocardial infarction is nominally the most important co-morbidity in patients with chronic obstructive pulmonary disease, and the one with the greatest potential for treatment and prevention to improve the overall prognosis of chronic obstructive pulmonary disease patients. We assessed the extent of myocardial infarction and other co-morbidities in individuals with chronic obstructive pulmonary disease in the general population. METHODS AND
RESULTS: We used individual participant data for the entire Danish population from 1980 through 2006, comprising 140 million person-years of follow-up. We used information from four national Danish registries with 100% follow-up and detected ever-diagnosed chronic obstructive pulmonary disease (n = 313,958) and incident cases of a first myocardial infarction (n = 422,344), lung cancer (n = 116,629), hip fracture (n = 53,756), depression (n = 93 038), and diabetes mellitus (n = 292 228). Multivariate adjusted hazard ratios for life-time association with ever-diagnosed chronic obstructive pulmonary disease were 1.26 (95% CI 1.25-1.27) for myocardial infarction, 2.05 (2.03-2.08) for lung cancer, 2.12 (2.07-2.17) for hip fracture, 1.74 (1.70-1.77) for depression, and 1.21 (1.20-1.23) for diabetes mellitus, compared with controls; these risk estimates were highest in women and the youngest age groups. Before the first hospitalization with chronic obstructive pulmonary disease, multivariate adjusted odds ratios were 1.47 (1.44-1.49) for myocardial infarction, 3.68 (3.52-3.84) for lung cancer, 1.16 (1.13-1.18) for hip fracture, 1.88 (1.80-1.96) for depression, and 1.16 (1.13-1.18) for diabetes mellitus, compared with matched controls. Corresponding values after a chronic obstructive pulmonary disease hospitalization were 0.74 (0.73-0.76), 1.48 (1.45-1.51), 1.23 (1.20-1.27), 1.21 (1.18-1.24), and 0.83 (0.81-0.85), respectively.
CONCLUSION: Chronic obstructive pulmonary disease was associated with higher rates of myocardial infarction, lung cancer, diabetes, hip fracture, and depression, but the strength of these associations was modified after a first admission for chronic obstructive pulmonary disease. These associations may be related to common genetic and/or lifestyle/environmental risk factors, and therefore these factors are likely to have an adverse health impact rather than chronic obstructive pulmonary disease per se.

Entities:  

Mesh:

Year:  2011        PMID: 21875856     DOI: 10.1093/eurheartj/ehr338

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  25 in total

1.  Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter.

Authors:  Javier García Seara; Sergio Raposeiras Roubin; Francisco Gude Sampedro; Vanessa Balboa Barreiro; José Martínez Sande; Moisés Rodriguez Mañero; Pilar Cabans Grandio; Belen Alvarez; José González Juanatey
Journal:  Clin Res Cardiol       Date:  2014-02-25       Impact factor: 5.460

2.  Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.

Authors:  Truls S Ingebrigtsen; Jacob L Marott; Børge G Nordestgaard; Peter Lange; Jesper Hallas; Morten Dahl; Jørgen Vestbo
Journal:  J Gen Intern Med       Date:  2014-09-23       Impact factor: 5.128

3.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Authors:  Shaun G Goodman; Daniel M Wojdyla; Jonathan P Piccini; Harvey D White; John F Paolini; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Manesh R Patel; Matthew W Sherwood; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Gunter Breithardt; Keith A A Fox; Robert M Califf
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

4.  Airway obstruction and the risk of myocardial infarction and death from coronary heart disease: a national health examination survey with a 33-year follow-up period.

Authors:  Tiina Mattila; Tuula Vasankari; Harri Rissanen; Paul Knekt; Pauli Puukka; Markku Heliövaara
Journal:  Eur J Epidemiol       Date:  2017-07-07       Impact factor: 8.082

5.  Value of Cardiopulmonary Exercise Testing in the Prognosis Assessment of Chronic Obstructive Pulmonary Disease Patients: A Retrospective, Multicentre Cohort Study.

Authors:  Ralf Ewert; Anne Obst; Andreas Mühle; Michael Halank; Jörg Winkler; Bernd Trümper; Gerhard Hoheisel; Andreas Hoheisel; Mark Wiersbitzky; Alexander Heine; Alexander Maiwald; Sven Gläser; Beate Stubbe
Journal:  Respiration       Date:  2021-11-19       Impact factor: 3.966

Review 6.  Depression and anxiety in patients with COPD.

Authors:  Abebaw M Yohannes; George S Alexopoulos
Journal:  Eur Respir Rev       Date:  2014-09

7.  Macrophage activation in stellate ganglia contributes to lung injury-induced arrhythmogenesis in male rats.

Authors:  Juan Hong; Ryan J Adam; Lie Gao; Taija Hahka; Zhiqiu Xia; Dong Wang; Thomas A Nicholas; Irving H Zucker; Steven J Lisco; Han-Jun Wang
Journal:  Acta Physiol (Oxf)       Date:  2021-04-14       Impact factor: 7.523

Review 8.  Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony.

Authors:  Aibek E Mirrakhimov
Journal:  Cardiovasc Diabetol       Date:  2012-10-27       Impact factor: 9.951

Review 9.  Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.

Authors:  Kieran J Rothnie; Ruoling Yan; Liam Smeeth; Jennifer K Quint
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

10.  Differential expression of C-reactive protein and serum amyloid A in different cell types in the lung tissue of chronic obstructive pulmonary disease patients.

Authors:  Carmen Calero; Elena Arellano; Jose Luis Lopez-Villalobos; Verónica Sánchez-López; Nicolás Moreno-Mata; José Luis López-Campos
Journal:  BMC Pulm Med       Date:  2014-05-30       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.